News

BIOGEN TO REPORT FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS FEBRUARY 12, 2025

FDA Accepts LEQEMBI® (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s Disease

Biogen Appoints Adam Feire as Head of Business Development and External Innovation

Biogen to Present at the 43rd Annual J.P. Morgan Healthcare Conference